Piridoxilate-induced calcium oxalate calculi: a new drug-induced metabolic nephrolithiasis.
During the last 4 years we collected 27 specimens of calcium oxalate nephrolithiasis in patients receiving long-term treatment with piridoxilate, a drug composed of an equimolar combination of glyoxylate and pyridoxine. The mean duration of treatment was 3.6 years (range 4 months to 10 years) and the mean daily dose was 580 mg. piridoxilate, which contained 160 mg. glyoxylate. Calculi often recurred, with an average number of 9.9 per patient, and an open operation, shock wave lithotripsy or percutaneous nephrolithotomy was required in 22 patients (81 per cent). Oxalate excretion was 727 +/- 246 mumol. per day while on the drug and 382 +/- 201 mumol. per day after the drug was withdrawn. Whewellite was the major component of calculi in all cases but the stones exhibited a peculiar morphological arrangement, with multiple small indentations and a fine mamillary structure. Freshly voided urine specimens contained unusual crystals, which on infrared spectroscopy were composed of calcium oxalate trihydrate, a variety of crystal never observed previously in human urine. Piridoxilate-induced calcium oxalate nephrolithiasis is a new variety of metabolic drug-induced nephrolithiasis. Our observations suggest that even large doses of pyridoxine may be unable to prevent the excessive production of oxalate from glyoxylate.
D000328:Adult; D000368:Aged; D002129:Calcium Oxalate / Q000032:analysis*; D003327:Coronary Disease / Q000188:drug therapy; D005260:Female; D006801:Humans; D006959:Hyperoxaluria / Q000139:chemically induced; D007669:Kidney Calculi / Q000032:analysis / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D011736:Pyridoxine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
C016189:whewellite; C001310:pyridoxilate; D002129:Calcium Oxalate; D011736:Pyridoxine